HDAC inhibition unlocks tumor plasticity and enhances immunotherapy response in Myc-Driven Small Cell Lung Cancer
Authors:
Preprint
Abstract
SUMMARY: Small Cell Lung Cancer (SCLC) is a highly aggressive malignancy, accounting for approximately 15% of all lung cancer cases. Characterized by low immunogenicity, SCLC may utilize epigenetic mechanisms to evade immune detection. Here, we demonstrate that entinostat, a class I histone deacetylase inhibitor (HDACi) upregulates immune-related genes in human SCLC cells. In vivo, we confirmed entinostat treatment increased expression of immunecheckpoint ligands and antigen presentation machinery in Myc-driven tumors in a Rb1/Trp53/Myc T58A (RPM) SCLC mouse model, while shifting tumors from a neuroendocrine(NE)-high to a NE-low phenotype. Notably, combining entinostat with anti-PD-1 immunotherapy significantly enhances T-cell infiltration, suppresses tumor growth, and prolongs survival in RPM allograft models. These findings underscore the potential of entinostat to reprogram the immunological landscape and NE status of SCLC, enhance immune checkpoint blockade efficacy, and improve therapeutic outcomes.Keywords
All Related Versions
- Published version: Molecular Cancer Therapeutics, 25 (10), OF1.
This publication has 56 references indexed in Scilit:
- Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer CellsAntioxidants & Redox Signaling, 2015
- Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2Genome Biology, 2014
- Small cell lung cancer: Where do we go from here?Cancer, 2014
- GSVA: gene set variation analysis for microarray and RNA-Seq dataBMC Bioinformatics, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRtNature Protocols, 2009
- Fast and accurate short read alignment with Burrows–Wheeler transformBioinformatics, 2009
- Distinct Role of Antigen-Specific T Helper Type 1 (Th1) and Th2 Cells in Tumor Eradication in VivoJournal of Experimental Medicine, 1999
- Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung CancerJournal of Clinical Oncology, 1999
- Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer.Journal of Experimental Medicine, 1985